Fréquence des incidentalomes lors d'un examen PET/CT effectué pour une pathologie oncologique

Contexte¦Le PET/CT au 18Fluor (FDG) fait aujourd'hui partie intégrante des moyens diagnostiques¦à disposition pour la stadification des cancers suspectés ou connus. Il n'est pas rare de¦découvrir des lésions fortuites.¦Objectifs¦Notre but était de déterminer la fréquence des lésions tumorales ou non, cliniquement¦silencieuses (incidentalomes), chez des patients consécutifs non sélectionnés examinés¦par PET/CT au FDG pour un cancer connu ou supposé au sein du bassin populationnel¦du CHUV.¦Méthode¦Nous avons rétrospectivement lu les 1226 des rapports d'examens faits d'août 2009 à¦juillet 2010 pour toute indication oncologique et relevé les lésions de découverte¦fortuite et leur localisation, avant de rechercher leur investigation et leur prise en¦charge.¦Résultats¦Nous avons retenu 309 lésions fortuites chez 260 patients (25,2% des rapports lus),¦dont 141 chez 127 patients investiguées. Ont été relevés 31 patients présentant 32¦incidentalomes (2,6%), dont 6 étaient malins, 6 pré-malins et 20 bénins, soit un taux de¦1% pour les malins et pré-malins. Les sites les plus fréquents étaient les mêmes que¦dans la littérature, à savoir la thyroïde, le poumon, la sphère colorectale (lésions prémalignes¦uniquement) et les lymphomes. Pour ces trois derniers, les lésions étaient¦moins fréquentes que ce qui est rapporté. Tous ces foyers sont à investiguer¦soigneusement, afin de différencier une nouvelle atteinte d'une métastase.¦Conclusion¦En tant que première étude suisse sur le sujet, nous obtenons 1% d'incidentalomes¦(pré)malins, soit l'équivalent de la limite inférieure de la littérature, dans des sites¦similaires. Une amélioration serait possible en augmentant l'attention portée aux lésions¦jugées peu significatives. A l'instar de nombreuses autres études, nous sommes aussi¦confrontés au problème lié à l'interprétation des foyers de captation et à la nonspécificité¦du FDG.

Phase II study of imatinib in advanced chordoma.

PURPOSE: To explore the antitumor activity of imatinib in patients with advanced platelet-derived growth factor β (PDGFB)/PDGF receptor β (PDGFRB)-positive chordomas.¦PATIENTS AND METHODS: In a collaborative Italian-Swiss, prospective, phase II clinical study conducted from November 2004 through April 2006, 56 patients with advanced PDGFB and/or PDGFRB chordoma received 800 mg/d of imatinib until progression. The primary end point was the overall tumor response rate (ORR), defined by RECIST. Secondary, exploratory end points included tissue response (ie, changes in tumor density or signal intensity/contrast enhancement, and/or [18F]-fluorodeoxyglucose positron emission tomography [PET] uptake), overall survival, progression-free survival (PFS), and pain score.¦RESULTS: Among 50 patients evaluable by RECIST, the best response was one partial response (PR) obtained at 6 months (ORR, 2%). There were 35 patients with stable disease (SD, 70%) and a 64% clinical benefit rate (ie, RECIST complete response + PR + SD ≥ 6 months). A minor dimensional response (< 20%) was detected in nine patients. A maximum standard uptake value decrease ≥ 25% was observed in 10 (39%) of 26 patients evaluable for PET response at 3 months. Changes in the Brief Pain Inventory score were consistent with the response assessment. Median PFS (intention-to-treat population, 56 patients) was 9 months. No unexpected toxicities were observed.¦CONCLUSION: This is the largest phase II study in chordoma to date. It confirms anecdotal evidence that imatinib has antitumor activity in this orphan disease, and therefore, it is worth further investigation.

The use of different types of thermoluminescent dosimeters to measure extremity doses in nuclear medicine

Depth-dose curves in LiF detectors of different effective thicknesses, together with their responses, were calculated for typical nuclear medicine radiation fields with 99mTc, 18F and 90Y sources. Responses were analysed in function of the radionuclide, detector effective thickness and irradiation geometry. On the other hand the results of the nuclear medicine measurement campaign of the ORAMED project were presented focussing on the dose distribution across the hand and on the appropriate position to wear the dosimeter.According to the results, thin LiF detectors provide better responses in all cases. Its use is essential for 18F, since thick dosimeters can underestimate Hp(0.07) up to a 50% because of the very inhomogeneous dose deposition on the active layer. The preliminary results of the measurement campaign showed that the index tip of the non-dominant hand is usually the most exposed position among the 22 monitored positions. It was also found that, in average, wrist dosimeters are likely to underestimate the maximum skin dose by a factor of the order of 20. This factor is reduced to around 6 for a ring dosimeter worn on the base of the index of the non-dominant hand. Thus, for typical nuclear medicine procedures, the base of the index of the non-dominant hand is recommended as the best monitoring option.

Relationship between imaging biomarkers, age, progression and symptom severity in Alzheimer's disease.

The early diagnostic value of glucose hypometabolism and atrophy as potential neuroimaging biomarkers of mild cognitive impairment (MCI) and Alzheimer's disease (AD) have been extensively explored using [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) and structural magnetic resonance imaging (MRI). The vast majority of previous imaging studies neglected the effects of single factors, such as age, symptom severity or time to conversion in MCI thus limiting generalisability of results across studies. Here, we investigated the impact of these factors on metabolic and structural differences. FDG-PET and MRI data from AD patients (n = 80), MCI converters (n = 65) and MCI non-converters (n = 64) were compared to data of healthy subjects (n = 79). All patient groups were split into subgroups by age, time to conversion (for MCI), or symptom severity and compared to the control group. AD patients showed a strongly age-dependent pattern, with younger patients showing significantly more extensive reductions in gray matter volume and glucose utilisation. In the MCI converter group, the amount of glucose utilisation reduction was linked to the time to conversion but not to atrophy. Our findings indicate that FDG-PET might be more closely linked to future cognitive decline whilst MRI being more closely related to the current cognitive state reflects potentially irreversible damage.

Synthesis of F-18-labeled cyclic-[RGDfK] peptides for PET imaging of angiogenesis

Objectives: αvβ3 integrin is of great interest for tumor targeting because of its high concentration in tumor tissue. It recognizes ligands containing an arginine-glycine-aspartate motif (RGD), and a number of RGD-containing peptides have been developed as PET imaging probes of angiogenesis. We synthesized a series of 18F-labeled cyclic-[RGDfK] peptides for in vivo imaging of αvβ3 expression. Our F-18 labeled prosthetic groups were attached to the αvβ3 ligand via click chemistry, and the reaction conditions (time, temperature, solvent and pH) were optimized by using single modified amino acids.Methods: Seven amino acids were selected considering their different biochemical properties (polarity, total charge, presence of aromatic ring and heteroatom). All the amino acids were modified by the introduction of azido moiety to allow the interaction with alkyne prosthetic groups. Once the conditions of the click chemistry were optimized, the prosthetic groups were also coupled with the cyclic-[RGDfK] exhibiting an azido function. 4- Trimethylammonium-nitrobenzene triflate was used as precursor for the radiosynthesis of the prosthetic groups. The fluorination was carried out with K2CO3/K2.2.2 in CH3CN at 95 oC, and the nitro group was reduced with NaBH4 and Pd/C in MeOH. The resulting 18F-aniline was subsequently coupled to alkynoic acids to yield the final F-18 labeled prosthetic groups. Finally, the prosthetic groups were attached to the peptides via Huisgen's cycloaddition. Figure 1. F-18 labeled αvβ3 ligand.Results: Our new prosthetic groups were successfully clicked to the modified amino acids and to the cyclic- [RGDfK], and the reactions were almost quantitative within 1 to 3.5 h. The pH of the reaction did not influence the reaction kinetic and yield. The four steps of the F-18 labeling were completely automated providing the final products in quantities and yields practical for PET imaging. IC50 values of our ligands for αvβ3 and α5β1 demonstrated a high selectivity of our compounds towards αvβ3, as well as the negligible effect of the prosthetic groups on the affinity of the ligand to its receptor, as confirmed by the prediction of the molecular modeling.Conclusions: We have successfully synthesized novel F-18 labeled prosthetic groups, as well as novel PET imaging probes of αvβ3 expression. The reaction conditions of the Huisgen's cycloaddition were optimized with selected modified amino acids, and subsequently transposed to the cyclic-[RGDfK] peptide. IC50 data demonstrate that our 18F-labeled ligands were selective for αvβ3. In vivo microPET/CT studies in tumor bearing mice are underway.

Generative FDG-PET and MRI model of aging and disease progression in Alzheimer's disease.

The failure of current strategies to provide an explanation for controversial findings on the pattern of pathophysiological changes in Alzheimer's Disease (AD) motivates the necessity to develop new integrative approaches based on multi-modal neuroimaging data that captures various aspects of disease pathology. Previous studies using [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) and structural magnetic resonance imaging (sMRI) report controversial results about time-line, spatial extent and magnitude of glucose hypometabolism and atrophy in AD that depend on clinical and demographic characteristics of the studied populations. Here, we provide and validate at a group level a generative anatomical model of glucose hypo-metabolism and atrophy progression in AD based on FDG-PET and sMRI data of 80 patients and 79 healthy controls to describe expected age and symptom severity related changes in AD relative to a baseline provided by healthy aging. We demonstrate a high level of anatomical accuracy for both modalities yielding strongly age- and symptom-severity- dependant glucose hypometabolism in temporal, parietal and precuneal regions and a more extensive network of atrophy in hippocampal, temporal, parietal, occipital and posterior caudate regions. The model suggests greater and more consistent changes in FDG-PET compared to sMRI at earlier and the inversion of this pattern at more advanced AD stages. Our model describes, integrates and predicts characteristic patterns of AD related pathology, uncontaminated by normal age effects, derived from multi-modal data. It further provides an integrative explanation for findings suggesting a dissociation between early- and late-onset AD. The generative model offers a basis for further development of individualized biomarkers allowing accurate early diagnosis and treatment evaluation.